Adaptive Biotechnologies (ADPT) stock price, revenue, and financials

Adaptive Biotechnologies market cap is $4.9 b, and annual revenue was $85.07 m in FY 2019

$4.9 B

ADPT Mkt cap, 29-May-2020

$20.9 M

Adaptive Biotechnologies Revenue Q1, 2020
Adaptive Biotechnologies Gross profit (Q1, 2020)15.6 M
Adaptive Biotechnologies Gross profit margin (Q1, 2020), %74.4%
Adaptive Biotechnologies Net income (Q1, 2020)-31.4 M
Adaptive Biotechnologies EBIT (Q1, 2020)-34.6 M
Adaptive Biotechnologies Cash, 31-Mar-2020212.7 M
Adaptive Biotechnologies EV4.7 B

Adaptive Biotechnologies Revenue

Adaptive Biotechnologies revenue was $85.07 m in FY, 2019

Embed Graph

Adaptive Biotechnologies Revenue Breakdown

Embed Graph

Adaptive Biotechnologies revenue breakdown by business segment: 59.2% from Sequencing revenue and 40.8% from Development revenue

Adaptive Biotechnologies Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

38.4m55.7m85.1m

Revenue growth, %

45%

Cost of goods sold

15.7m19.7m22.3m

Gross profit

22.8m36.0m62.8m

Gross profit Margin, %

59%65%74%

Sales and marketing expense

16.8m24.5m38.5m

R&D expense

32.0m39.2m70.7m

General and administrative expense

15.9m20.4m30.3m

Operating expense total

65.5m84.1m141.2m

Depreciation and amortization

1.7m

EBIT

(44.5m)(49.8m)(78.4m)

EBIT margin, %

(116%)(89%)(92%)

Interest income

1.6m3.3m9.8m

Net Income

(42.8m)(46.4m)(68.6m)

Quarterly

USDQ2, 2019Q3, 2019Q1, 2020

Revenue

22.1m26.1m20.9m

Cost of goods sold

5.7m5.6m5.3m

Gross profit

16.4m20.5m15.6m

Gross profit Margin, %

74%79%74%

Sales and marketing expense

8.9m9.1m14.0m

R&D expense

16.5m20.5m23.9m

General and administrative expense

6.7m8.5m11.8m

Operating expense total

32.5m38.5m50.2m

Depreciation and amortization

423.0k428.0k424.0k

EBIT

(16.1m)(18.1m)(34.6m)

EBIT margin, %

(73%)(69%)(166%)

Interest income

446.0k4.1m2.9m

Income tax expense

(323.0k)

Net Income

(15.7m)(13.9m)(31.4m)

Adaptive Biotechnologies Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

83.3m55.0m96.6m

Accounts Receivable

5.6m4.8m12.7m

Prepaid Expenses

2.7m3.1m14.1m

Inventories

4.8m7.8m9.1m

Current Assets

205.2m180.7m612.7m

PP&E

14.0m19.1m60.4m

Goodwill

119.0m

Total Assets

362.5m332.7m912.3m

Accounts Payable

2.0m1.8m4.5m

Short-term debt

8.4m

Current Liabilities

21.0m22.8m78.3m

Long-term debt

36.6m

Total Debt

45.0m

Total Liabilities

25.8m29.9m341.3m

Common Stock

1.0k1.0k12.0k

Preferred Stock

561.3m560.9m

Additional Paid-in Capital

25.0m37.9m935.8m

Retained Earnings

(249.4m)(295.9m)(365.5m)

Total Equity

336.7m302.7m571.0m

Financial Leverage

1.1 x1.1 x1.6 x

Quarterly

USDQ2, 2019Q3, 2019Q1, 2020

Cash

48.5m74.9m212.7m

Accounts Receivable

7.3m9.3m9.4m

Prepaid Expenses

4.0m10.0m9.6m

Inventories

8.0m8.7m10.5m

Current Assets

442.3m601.4m584.6m

PP&E

22.3m46.5m25.0m

Goodwill

119.0m119.0m119.0m

Total Assets

601.4m917.4m874.9m

Accounts Payable

2.9m2.4m3.9m

Short-term debt

7.5m8.0m1.5m

Current Liabilities

74.9m73.4m78.0m

Long-term debt

23.4m36.5m

Total Debt

7.5m31.4m38.0m

Total Liabilities

323.8m331.5m323.3m

Common Stock

1.0k12.0k12.0k

Additional Paid-in Capital

46.2m930.2m945.0m

Retained Earnings

(330.9m)(344.9m)(396.8m)

Total Equity

(284.4m)585.9m551.6m

Financial Leverage

-2.1 x1.6 x1.6 x

Adaptive Biotechnologies Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(42.8m)(46.4m)(68.6m)

Depreciation and Amortization

5.8m6.0m1.7m

Accounts Receivable

(2.4m)775.0k(7.8m)

Inventories

(2.7m)(3.0m)(1.2m)

Accounts Payable

(1.5m)2.2m6.1m

Cash From Operating Activities

(34.9m)(32.3m)205.4m

Purchases of PP&E

(2.4m)(6.3m)(11.2m)

Cash From Investing Activities

36.4m736.0k(481.7m)

Cash From Financing Activities

50.0m1.2m319.9m

Net Change in Cash

51.6m(30.3m)43.6m

Quarterly

USDQ2, 2019Q3, 2019Q1, 2020

Net Income

(34.0m)(48.0m)(31.4m)

Depreciation and Amortization

3.7m5.7m2.0m

Accounts Receivable

(2.4m)(4.4m)3.3m

Inventories

(166.0k)(829.0k)(1.4m)

Accounts Payable

1.3m3.1m(4.6m)

Cash From Operating Activities

262.3m232.2m(31.6m)

Purchases of PP&E

(5.4m)(8.8m)(3.0m)

Cash From Investing Activities

(267.5m)(528.4m)142.8m

Cash From Financing Activities

(1.4m)318.2m5.0m

Net Change in Cash

(6.6m)22.0m116.1m

Adaptive Biotechnologies Ratios

USDY, 2020

EV/EBIT

-136.8 x

EV/CFO

-149.8 x

Financial Leverage

1.6 x

Adaptive Biotechnologies Operating Metrics

FY, 2018

Immune Receptors Characteristics in Database

20 b

Partners

125

Product Lines

2

Adaptive Biotechnologies Employee Rating

3.945 votes
Culture & Values
4.0
Work/Life Balance
3.5
Senior Management
3.8
Salary & Benefits
3.9
Career Opportunities
3.8
Source